Edited by Mary Kay Bader, R.N., M.S.N., CCNS We were wondering if anyone has had experience with transcutaneous pacing or transvenously pacing patients who are in their goal of 32-34°C. Do you have any problems with capture and so on?Therapeutic hypothermia (TH), now referred to as targeted temperature management (TTM), is endorsed by the American Heart Association and International Liaison Committee on Resuscitation (ILCOR; Neumar et al., 2010). This is the standard of practice for post resuscitation care of patients whose initial pulseless rhythm is identified as ventricular fibrillation (VF) or ventricular tachycardia (VT). As with many medical therapies, risks as well as therapeutic benefit are associated with TTM (Polderman, 2009).Cardiac arrhythmias and ECG changes are common in TH, with the incidence increasing as core body temperature decreases. One potential side effect of TH in post cardiac arrest patients is bradycardia. A thorough review of the TTM literature reveals minimal publications documenting the need for temporary cardiac pacing. In 2006, the University of Minnesota published a case report of two patients requiring temporary cardiac pacing (in the form of transcutaneous pacing) for hemodynamic stability (Ho et al., 2007). Ho and others did not report any difficulties with the ability to acquire capture and maintain adequate transcutaneous pacing. Several animal studies have demonstrated improved cardiac function and hemodynamic stability post rewarming after undergoing severe hypothermia (24°C) and being treated with temporary pacing. The main outcome of these studies was to show a more rapid rate of rewarming when temporary pacing was utilized. (Dixon et al., 1997). Neither human retrospective studies nor prospective randomized controlled trials have been published demonstrating the benefit of temporary cardiac pacing in patients undergoing mild or moderate therapeutic hypothermia.Our experience at Harborview Medical Center in Seattle, Washington, is that temporary cardiac pacing is not typically warranted for patients experiencing mild ( > 34°C) or moderate (30-34°C) hypothermia. In 2009, we published one of the largest single center retrospective studies, n = 204 (Don et al., 2009). No clinical conditions warranted temporary cardiac pacing in any of the 132 out of 204 patients who achieved the goal temperature of 33°C. No evidence exists to suggest that temporary cardiac pacing (transcutaneous or transvenous) is not safe or reliable in the hypothermic patient. In the setting of hypothermia and hemodynamic instability, if temporary cardiac pacing is indicated, then it should be cautiously considered along with other chronotropic and inotropic medications to improve cerebral blood flow, restore end-organ perfusion, and prevent further cardiovascular collapse. The mode of temporary pacing (transcutaneous vs. transvenous) should also be carefully evaluated prior to use.
ReferencesDixon RG, Dougherty JM, White LJ, et al. Transcutaneous pacing in a hypothermic dog model. Ann Emerg Med 1997;32:602...